A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

Inclusion Criteria: * Voluntary agreement to provide written informed consent. * Predicted survival ≥ 12 weeks. * According to UICC/AJCC 8th Edition, histologically and/or cytologically-confirmed, cannot be surgically removed, locally advanced or metastatic NSCLC. * Is willing and able to provide an adequate archival tumor tissue sample * Has relapsed from or is refractory to standard treatment and had received both platinum-based therapy and immunotherapy. * Measurable lesion according to RECIST 1.1. * Documented HER2 exon 20 insertion mutation. * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. * Adequate organ function. * For female subjects: should be surgically sterilized, postmenopausal, or agree to use a medically approved contraceptive (such as an intrauterine device, contraceptives, or condoms) during study treatment and within 6 months after the end of study, the blood pregnancy test within 7 days of study enrollment must be negative and must be non-lactating. Male subjects: Patients who should be surgically sterilized or agree to use a medically approved contraceptive during the study treatment period and within 6 months after the end of the study. * Willing and able to follow trial and follow-up procedures. Exclusion Criteria: * No known EGFR, ALK, ROS1, RET, NTRK, MET 14 or BRAF V600E mutation. * Patient has had previous treatment with HER2-targeted therapy prior to study participation. * History of major surgery within 4 weeks of …